ORION-1 will provide information from 6 through 9 months on the potential for inclisiran to deliver sustained reductions in LDL-C either as a biannual or quarterly regimen safely and identify the dose and dosing regimen to be used in future Phase 3 CVOTs.

Clinical Topics: Dyslipidemia, Prevention, Lipid Metabolism, Nonstatins, Novel Agents, Statins

Keywords: ACC17, ACC Annual Scientific Session, Atherosclerosis, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Lipids, Primary Prevention, RNA Interference, RNA, Small Interfering

< Back to Listings